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within 30 days of the prescription’s origination date. RESULTS: Using the PQA-
developed PMN measure, these 100 pharmacies had an overall PMN rate of 9.3%. 
The measure could be calculated using the pharmacy transaction data; however, 
some adjustments (e.g., assumption that patient did not receive drug at another 
pharmacy) had to be made. CONCLUSIONS: Retail pharmacy data can be used to 
measure quality indicators, like PMN. These measures will have limitations, as 
do other quality indicator measures.  
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OBJECTIVES: We present the methodology for a near-real-time 
Pharmacovigilance & Drug Safety System (PDSS) to detect relationships between 
indications, drugs and outcomes. Combinations are user-selectable from a 
library of clinical scenarios including indications, agents and outcomes. 
Exemplary results for drug-outcome pairs from the PDSS are illustrated. 
METHODS: Deidentified claims data for five million individuals covering a 12-
month span was analyzed. A ‘Heat-Map’ was generated with relative risk (RR) for 
combinations of 73 DDCs and 39 HOIs. Clinical indications (on- and off-label), 
presence of drug, and outcomes were identified as, respectively,1+ ICD-9 
claim(s), 1+ NDC codes for a drug refill, and outcome code present in months 6-
12 but not in month 1-6. RR and Chi-Squared were calculated for every 
combination (SAS 9.3). RESULTS: PDSS generated 47,319 indication-drug-
outcome combinations. Run time was less than 48 hours. At a nominal threshold 
of at least 5 unique patients chi-square (X2) value of over 5, 13,094 (28%) of the 
combinations were identified for further inspection. Example results included: 
GERD-PPI-Bleeding:0.648 (x2=139); GERD-PPI-Fracture:1.42(x2=11.1); Hypertension-
ACEI-CHF:0.81(x2=19.5); Hypertension-metoprolol-Renal failure:1.78(x2=86.7); 
Non-valvular Atrial fibrillation-Dabigatran-Bleeding:1.1(x2=0.2); Valvular Atrial 
fibrillation-Dabigatran-Bleeding:1.3 (x2=2.6); mechanical heart valve-dabigatran-
stroke:8.76(x2=6.5). CONCLUSIONS: The PDSS rapidly quantifies indication-drug-
outcome combinations from real-world data. Such a system can provide 
prospective and continuous drug surveillance and comparative effectiveness & 
harms analysis. This can permit more efficient targeting of further analyses. 
Finally, the PDSS is constructed such that it is rapidly able to incorporate new 
indication, drug, and/or outcome data from claims or clinical (i.e. EMR) data sets.  
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OBJECTIVES: To examine the concordance in diabetes diagnosis between 
electronic medical records (EMR) and claims data and to explore an appropriate 
definition for diabetes in EMR data. METHODS: Retrospective study using the 
Linked Quintile EMR and MarketScan Commercial and Medicare Databases 
(MSN). Patients with at least one EMR every year and continuous enrollment in 
MSN between January 1, 2009 through December 31, 2011 were included in the 
study. Patients with at least one inpatient or two outpatient claims for diabetes 
(ICD-9-CM 250.xx) in MSN were identified as diabetic patients. Diabetes was 
defined in the EMR data using various criteria, including HbA1C≥6.5%, diabetes in 
the problem list, any insulin prescription, ≥2 oral anti-diabetic agents, and ≥2 
abnormal fasting plasma glucose tests. An extended definition of diabetes based 
on the presence of any of the criteria mentioned above was also evaluated. 
RESULTS: Among the 257,899 patients meeting the study inclusion criteria, 
34,383 were identified as diabetic patients using MSN claims. When the extended 
definition was used, 27,219 patients were defined as diabetic in EMR, an 11.8% 
increase compared with those identified using the HbA1C≥6.5% criterion, and 
2.35 times of those with a diabetes diagnosis in the problem list. Assuming 
claims to be the gold standard, the extended definition also had a higher 
sensitivity at 79.2% (versus 70.8% when HbA1c≥6.5% criterion was used alone 
and 33.6% when the criterion of diabetes on problem list was used alone). The 
specificity of the extended definition was 97.9%. CONCLUSIONS: This study 
explored the feasibility of identifying the diabetic patients in the Quintile EMR 
data and confirmed good concordance of the diabetes definition between EMRs 
and claims. When linked EMR and claims data are used, the diagnosis of diabetes 




HOW DO PHARMACEUTICAL MARGINS VARY BY REGION, THERAPEUTIC AREA 
AND COUNTRY GROSS DOMESTIC PRODUCT?  
Donze B, Patel P 
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OBJECTIVES: Mapping the pharmaceutical distribution margin variations 
according to country wealth and therapy areas may provide insight into the 
developing trends of medicine supply across the globe. To confirm any trends, 
we compared pharmaceutical margins for diabetic, multiple sclerosis and 
oncology drugs in various countries to the country gross domestic product (GDP). 
METHODS: Using data from PRICENTRICTM, we collected ex-factory and public 
prices (excl. VAT) for various branded products from three therapy areas 
(diabetes, multiple sclerosis and oncology). Countries with unregulated 
distribution margins were excluded from the analysis. We calculated the average 
distribution margins between ex-factory price and public price across countries, 
regions and therapy areas. We also compared distribution margins to GDP per 
capita (International Monetary Fund 2012) to investigate trends between the two 
parameters. The analysis investigates two key areas: 1. Correlation between 
distribution margins across therapy areas and regions and 2: The relationship 
between pharmaceutical margins and GDP per capita across countries. RESULTS: 
In Asia-Pacific, we find that the distribution margins are higher for diabetic 
drugs (32%) than multiple sclerosis (23%) and oncology (16%). In Europe, a similar 
pattern follows: distribution margins in diabetes (28%), multiple sclerosis (12%) 
and oncology (12%). The margins in Middle-East-Africa and US however, remain 
constant across all three therapy areas. We found no correlation between the 
drug distribution margins and GDP aside from the Middle-East-African region, 
which showed a higher pharmaceutical margin in high GDP countries. 
CONCLUSIONS: Our analysis shows that pharmaceutical margins vary the most 
depending on region and therapy area with little correlation to the GDP per 
capita. Pharmaceutical distribution margins are higher in Asia-Pacific than in 
Middle-East-Africa, Europe and US.  
 
PRM66  
USE OF COMMON DATA MODEL TO MEANINGFULLY COMPARE TREATMENT 
PATTERNS FOR DEPRESSION AMONG DISPARATE DATABASES  
Reisinger S1, Powell G2, Dreyfus B3, Schneider G4 
1United BioSource Corporation, Harrisburg, PA, USA, 2GlaxoSmithKline, RTP, NC, USA, 3Bristol-
Myers Squibb, Wallingford, CT, USA, 4United BioSource Corporation, Lexington, MA, USA  
OBJECTIVES: Use of a Common Data Model (CDM) to standardize data format 
and assumptions facilitates consistent and efficient application of research 
methods across disparate data sources, producing meaningfully comparable 
results. This study compared treatment patterns for patients diagnosed with 
depression in 2008-09 across multiple observational databases, after all source 
data was transformed into a CDM format. METHODS: Newly diagnosed 
depression patients were identified from 5 Administrative Claims and Electronic 
Health Record (EHR) databases, comprising ~300 million patients previously 
transformed into a CDM format. Patterns of initial treatment for anti-depressant 
drug classes (e.g. SSRI, SNRI, TCA, MAOI, Other) were analyzed using a common 
CDM analysis module. The Proportion of Days Covered (PDC) as well as patterns 
of continuation, discontinuation, augmentation, and switching was calculated 
for 365 days immediately following initial treatment. RESULTS: SSRIs were the 
most common first line treatment (72-75% across databases), followed by Other 
antidepressants (12-17%). The patterns of continuation varied by type of 
database: Government Claims (5%), Commercial Claims (14-15%), EHR (32%). 
Discontinuation was consistent across all Claims (65-69%) with EHR lower (46%). 
Switching rate (12-14%) and specific patterns of switching were consistent across 
all database types. Augmentation rate was consistent across all databases (7-8%); 
with the exception Government Claims (13%). The pattern of augmentation was 
variable depending on type of database. PDC was consistent across Claims (25-
28%) but varied from EHR (57%). On average across databases, TCAs had lowest 
PDC (25-28% Claims, 57% EHR) while SNRI’s had the highest (29-44% Claims, 53% 
EHR). Analysis was completed on all databases in less than two days. 
CONCLUSIONS: Common Data Models provide an efficient way of enabling 
meaningful comparisons across disparate data sources. Differences in results are 
likely due to differences in underlying populations, data capture process, and/or 




PREPARATION OF A HOSPITAL DATASET FOR ANALYSIS PRIOR TO A HOSPITAL 
AND HEALTH INSURER MERGER  
Jiandani S, Lovett A 
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OBJECTIVES: To provide a source document in the creation of a dataset for a 
hospital and health insurer merger. METHODS: A review of the literature was 
performed to determine best practices in the development of a dataset to link 
hospital data with health insurance data. Peer reviewed articles and reports were 
retrieved from the published literature from 2002 to 2012. RESULTS: Results 
revealed a total of 30 articles and reports. A summary of this information is 
provided as a step-by-step guide on how to setup a dataset. The purpose of data 
collection should be discussed in detail. The data must be de-identified due to 
HIPAA regulations. Patient data, such as date of birth, hospital admission, 
discharge date, sex, and ICD-9 code can be combined to form an identifier that is 
nearly 100% unique and found in both hospital and payer databases. This is 
stored as a separate dataset. Additionally, a dataset from the payer should be 
extracted and stored. The resulting datasets can then be sent to a Data 
Coordinating Center, where data is evaluated for quality assurance and 
combined into one master dataset. Prior to combining datasets it is helpful to 
identify potential research outcomes of interest to ensure that the variables are 
accurately represented by the data. CONCLUSIONS: Currently, there are few 
databases that allow researchers to follow a patient from hospital admission to 
post discharge. Researchers who obtain data offering a cross sectional view of a 
patient’s health status must find creative ways to link patients over time either 
making many assumptions or using various simulation methods. A hospital and 
health insurer merger offers a unique opportunity to develop a dataset to track 
patient outcomes.  
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Spontaneous reports (SRs) of suspected adverse events associated with 
biopharmaceuticals and other medical products are key sources for identifying 
potential new drug hazards. They are required by most regulatory agencies as 
well as large drug distribution projects, e.g., HIV/TB programs. The WHO collects 
these pharmacovigilance data from >100 countries. Many databases conform to 
WHO’s Council for International Organizations of Medical Sciences (CIOMS) 
standard data fields. B.R.I.D.G.E. TO DATA (www.bridgetodata.org), an 
international resource of database profiles, can serve as a template and 
complement the CIOMS effort. OBJECTIVES: Analyze SR database profiles and 
classify use of data fields. METHODS: We identified databases profiled in 
B.R.I.D.G.E. collecting SR data using two search criteria: Database 
Type=Spontaneous reporting systems; and Database Source=Spontaneous reports. 
Twenty of 198 profiles matched ≥1 criteria; frequency of use of the 75 data fields 
were compared. Based on use frequency, fields were categorized into Group 1 (G1 
- consensus in use of field among the set), Group 2 (G2 - use by ≥50% databases), 
or Group 3 (G3 - use by <50% databases). RESULTS: Of the 75 data fields, 53 (71%) 
were frequently used among databases with SR data: 21 (28%) were classified 
into G1 (e.g., Diagnosis data, Drug data), and 32 (43%) into G2 (e.g., Death 
recorded, Physician specialty). Fields utilized less frequently (n=22; 29%) 
comprised G3 (e.g., Medical Record Access, Linkage Capabilities). Analysis of G1 
revealed that a majority of SR databases are funded by government agencies, 
capture OTC & prescription drug use in inpatient & outpatient settings; however, 
diagnosis data are heterogeneously coded. Of the 25 fields on the CIOMS 
reporting form, 17 corresponded to G1, and 8 to G2. CONCLUSIONS: In this 
analysis, B.R.I.D.G.E. served as a screening tool to categorize data fields used in 
SR databases and successfully identified additional fields to complement the 
CIOMS effort.  
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OBJECTIVES: Ovid and Embase.com are two search engines that are commonly 
used for searching the Medline and Embase databases. The standard of practice 
for conducting a search for a systematic literature review seems to support the 
use of Ovid. Our objective was to discern the advantages and disadvantages of 
both the Embase.com and Ovid search engines. We sought to compare the two 
databases in the following ways: results of a search, and ease of searching. 
METHODS: We conducted several searches to see if there were any differences in 
results. We analyzed the variation in results to determine why the disparities 
existed. We wrote a step-by-step search guide and highlighted the 
differences/difficulties encountered. Using a set of written directions, we also 
asked researchers to conduct searches using both interfaces and rate ease of use 
on a scale of 0 through 5. Research was also conducted through websites and 
help desks to ascertain the disparities in content between the two search 
engines. RESULTS: There were differences in the search results between Ovid 
and Embase.com using the same search criteria. The coding of articles 
sometimes differed, but there were very few, if any, relevant articles that were 
missed by either engine. In terms of ease of use, Embase.com had lower scores 
indicating greater ease of use in searching, exporting into a reference manager, 
saving searches, and recalling data compared to Ovid. In the research assessing 
the differences in content through the company websites, we found that 
Embase.com alleged to contain articles published further in the past, include 
more conference abstracts, and update Emtree terms more frequently than did 
Ovid. CONCLUSIONS: There is no notable difference between Ovid and 
Embase.com in terms of search results when searching Embase and Medline. 
However, Embase.com was rated as easier to use in several domains compared 
to Ovid.  
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OBJECTIVES: Observational studies using administrative claims data are 
increasingly used for oncology outcomes research. The only population-based 
administrative data inclusive of disease stage and death from registries, 
however, are the SEER-Medicare data which exclude the under 65 population. 
Many state cancer registry and claims data linkages exist, but little is known 
about them. We conducted a literature review to identify and describe U.S. state-
level, population-based cancer data linkages. METHODS: PubMed was searched 
for all years using the keywords “registry,” “cancer OR oncology,” and “claims OR 
administrative.” Inclusion criteria were U.S. state cancer registries and 
administrative claims data linkages, exclusive of the SEER-Medicare database. 
RESULTS: A total of 687 abstracts were identified; 74 articles met the inclusion 
criteria. These papers represented 21 state cancer registries and linkages to 
Medicaid, Medicare, commercial insurance claims, state-level hospital discharge 
files, state-level screening program data, or state health care agency 
administrative files. Most linked Medicaid (N=12) and Medicare (N=9) data to 
assess quality of cancer care for specific types of cancer. Eighty percent of states 
specifically linked data on breast-cancer, 40% linked colorectal cancer, 25% 
linked on cervical, prostate or lung, and 40% were inclusive of all cancers. Only 
seven states (35%) linked commercial claims data or hospital discharge data 
(representing the under 65 population). CONCLUSIONS: Significant work is being 
conducted at the state level to generate cancer data, yet the under 65 population 
remains under-represented among linked cancer lives. Although fragmented, the 
existing linkages provide a foundation on which to build a more comprehensive 
oncology data system. Maintaining and expanding these data are critical for 
quality assessments, and disparity, outcomes and comparative effectiveness 
research. Barriers related to proprietary data and sustainable funding for 
linkages must be addressed before a data infrastructure that is broadly 
representative of the US national population can be generated.  
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OBJECTIVES: It’s important for health care policy makers, payers and drug 
manufacturers to identify Chronic Kidney Disease (CDK) patient stages in order 
to evaluate the prevalence, economic burden or market opportunities. The office 
based medical claims data, which contains ICD-9 diagnosis and treatment 
information of CDK stages, has very limited coverage. To identify more CDK 
patients, we built and compared varies of statistical models and machine 
learning algorithms to project CKD stages using prescription database. 
METHODS: The model data contained year 2011 patient level CKD stage 
indications, longitudinal drug therapies, days of supplies, titration rates, 
Demographic characteristics, payment type, and physician specialties, etc. The 
data were randomly divided into a training set (66.7%) and a validation set 
(33.3%). The classification models used were Logistic regression, linear/quadratic 
Discriminant, Classification and Regression Tree (CART), C4.5 decision tree, Logit 
Boost classification tree, Bayes learning networks, Support Vector Machine and 
Neural networks. Bagging and boosting techniques were also tested to improve 
the precision. RESULTS: Logistic regression showed the best classification 
accuracy out of all models. The overall correct classification rate was 66.8%, 
Kappa Statistics 0.35, F-measure 0.63 and receiver operating characteristic  
(ROC) area 0.75. Among all CDK stages, CDK stage 1-3 were predicted most 
accurately with True Positive Rate (TPR) 93% and 65% precision. ESRD  
was moderately identified with TPR 46% and precision 76%. CDK 4 was most 
difficult to identify, with TPR 9% and precision 40%. The bagging and boosting 
improved decision trees showed comparable results. CONCLUSIONS: The 
modern machine learning algorithms were proved to be more accurate in many 
cases but for the CKD dataset the classical logistic model worked out better. The 
logistic model could fairly classify severe CKD stages (4-5) patients from lower 
stages (1-3) using prescription information but it had hard time to separate CKD 
stage 4 from 5.  
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OBJECTIVES: Confounding issues have not been accommodated adequately in 
the public health literature of smoking. This study examines the impact of 
smoking on mortality for patients with diabetes using a propensity score 
matching approach. METHODS: We employed the National Health Interview 
Survey (NHIS) data from 1997 to 2001. Patients who were older than 18 and have 
been diagnosed with diabetes are included in the study. The study outcome was 
all cause mortality, where death records obtained from National Death Index 
were available through Dec. 31, 2006. Propensity score matching (PSM) was 
performed based upon patients’ smoking status. Time to event model was 
performed on the PS matched samples. RESULTS: There were 165,057 patients 
older than 18 participated NHIS survey between 1997 and 2001, of which, 10,194 
(6.18%) and had prior diabetes. Our estimation results suggest stop smoking for 
less than 5 years was associated with a 67% greater risk of death than having 
never smoked; stop smoking for more than 5 years did not have a different risk 
of mortality than those who never smoked. In addition, smoking 16-34 cigarettes 
per day was associated with 52% greater risk of death, and smoking more than 
34 cigarettes per day more than doubles the risk relative to the never smokers. 
CONCLUSIONS: This study indicates smoking reduced survival significantly for 
patients with diabetes; smoking cessation for more than 5 years prolonged 
survival. It provides important evidence to decision makers who attempt to 
advocate smoking cessation programs to patients with diabetes.  
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OBJECTIVES: To evaluate the impact of epidemiologically established risk 
factors, both singular and multiple, on the rates of AF and stroke in a large 
claims database. METHODS: Using patients in the Truven Health MarketScan® 
Commercial and Medicare Supplemental Databases with enrollment during the 
entirety of 2007 (baseline), six conditions were considered as risk factors for 
stroke and AF: age (grouped as <65, 65-74, 75+), heart failure (HF), hypertension 
(HTN), diabetes, renal insufficiency, and coronary artery disease. A single 
categorical variable was created reflecting each patient’s exact combination of 
these conditions. Using this variable as the single predictor, Cox proportional 
